PremiumThe FlyVaccinex reports Q3 EPS ($2.83) vs. ($15.25) last year Vaccinex provides update on ActivMAb platform Vaccinex to preset new biomarker data on HNSCC PremiumCompany AnnouncementsVaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns Vaccinex Provides Update on Alzheimer’s Treatment Trial Vaccinex provide update on findings for SIGNAL-AD Phase 1b/2 trial of pepinemab PremiumThe FlyVaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab Vaccinex files to sell 490,509 shares of common stock for holders Vaccinex Completes Key Study Phase for Alzheimer’s Drug 
